NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.32 -0.66 (-3.48 %)
(As of 09/23/2018 01:39 PM ET)
Previous Close$18.32
Today's Range$18.13 - $19.19
52-Week Range$9.00 - $21.71
Volume1.82 million shs
Average Volume527,803 shs
Market Capitalization$1.11 billion
P/E Ratio-6.52
Dividend YieldN/A
Beta3.72
Karyopharm Therapeutics logoKaryopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KPTI
CUSIPN/A
Phone617-658-0600

Debt

Debt-to-Equity RatioN/A
Current Ratio6.69
Quick Ratio6.69

Price-To-Earnings

Trailing P/E Ratio-6.52
Forward P/E Ratio-5.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.61 million
Price / Sales689.11
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book7.02

Profitability

EPS (Most Recent Fiscal Year)($2.81)
Net Income$-128,980,000.00
Net MarginsN/A
Return on Equity-97.85%
Return on Assets-75.93%

Miscellaneous

Employees154
Outstanding Shares60,560,000
Market Cap$1.11 billion

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its earnings results on Tuesday, August, 7th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.21. The business earned $19.89 million during the quarter, compared to analysts' expectations of $5.97 million. View Karyopharm Therapeutics' Earnings History.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Karyopharm Therapeutics.

What price target have analysts set for KPTI?

9 analysts have issued 12 month price targets for Karyopharm Therapeutics' shares. Their predictions range from $18.00 to $30.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $23.1250 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

What is the consensus analysts' recommendation for Karyopharm Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

What are Wall Street analysts saying about Karyopharm Therapeutics stock?

Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
  • 1. HC Wainwright analysts commented, "We base our $30 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta- refractory multiple myeloma, a 35% POS for selinexor in combination treatment for multiple myeloma, and a 25% POS for selinexor in DLBCL. We use a 4x P/S multiple and estimated YE18 fully diluted net cash of $2.20/ share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x." (8/29/2018)
  • 2. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (8/3/2018)
  • 3. Cantor Fitzgerald analysts commented, "KPTI reported top-line STORM data, which demonstrated a 25.4% ORR (2 CRs and 19 PRs) and 4.4 months DoR in penta-refractory myeloma patients. That means the company will be able to file an NDA for accelerated approval in this population in the U.S. and Europe." (4/30/2018)
  • 4. Canaccord Genuity analysts commented, "We had the pleasure of hosting Karyopharm CEO Michael Kauffman and CFO Mike Falvey for meetings with institutional investors in New York City. Overall, investors focused on upcoming and potentially registration-supporting datasets for lead drug candidate selinexor in two trials: STORM in penta-refractory multiple myeloma (April 30) and SADAL in relapsed/refractory diffuse large B-cell lymphoma (DLBCL, 2H). We came away with increased confidence that Accelerated Approval is a viable path for selinexor, continue to view the available data as indicative of benefit, and reiterate our BUY rating and $22 PT." (4/10/2018)

Who are some of Karyopharm Therapeutics' key competitors?

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the folowing people:
  • Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 55)
  • Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 48)
  • Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 37)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 57)
  • Mr. Michael F. Falvey, Exec. VP, CFO & Treasurer (Age 59)

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.14%), FMR LLC (2.54%), Point72 Asset Management L.P. (2.38%), Millennium Management LLC (1.72%), Northern Trust Corp (0.99%) and Emerald Advisers Inc. PA (1.13%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

Which major investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Millennium Management LLC, Trexquant Investment LP, TCW Group Inc., Cubist Systematic Strategies LLC and Dimensional Fund Advisors LP. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

Which major investors are buying Karyopharm Therapeutics stock?

KPTI stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Private Capital Advisors Inc., Macquarie Group Ltd., Frontier Capital Management Co. LLC, Northern Trust Corp and Renaissance Technologies LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $18.32.

How big of a company is Karyopharm Therapeutics?

Karyopharm Therapeutics has a market capitalization of $1.11 billion and generates $1.61 million in revenue each year. The company earns $-128,980,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Karyopharm Therapeutics employs 154 workers across the globe.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is http://www.karyopharm.com.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]


MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  192 (Vote Underperform)
Total Votes:  528
MarketBeat's community ratings are surveys of what our community members think about Karyopharm Therapeutics and other stocks. Vote "Outperform" if you believe KPTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KPTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2018 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel